Celecoxib augmentation of continuously ill patients with schizophrenia.
BACKGROUND
Previous reports have demonstrated a beneficial effect of celecoxib adjunctive therapy for patients with an acute exacerbation of schizophrenia. We investigated the effects of celecoxib augmentation of atypical antipsychotic medications for continuously symptomatic outpatient subjects with schizophrenia to further extend these findings. We hypothesized that celecoxib augmentation therapy would improve psychopathology ratings compared with placebo.


METHODS
Thirty-eight symptomatic outpatient subjects meeting DSM-IV criteria for schizophrenia and on a stable dose of an atypical antipsychotic medication for at least three months were randomized to receive 8 weeks of double blind placebo or celecoxib (400 mg/day) augmentation. Measures of psychopathology, functional disability, and extrapyramidal side effects were performed throughout the study.


RESULTS
The treatment cohorts did not differ on any of the clinical outcome measures.


CONCLUSIONS
Celecoxib augmentation of continuously ill outpatient subjects with schizophrenia did not improve clinical symptoms or measures of disability.
Rapaport
Mark Hyman
MH
Department of Psychiatry, Cedars-Sinai Medical Center, Los Angeles; Department of Psychiatry, Geffen School of Medicine, University of California - Los Angeles 90045, USA. mark.rapaport@cshs.org
Delrahim
Katia K
KK
Bresee
Catherine J
CJ
Maddux
Rachel E
RE
Ahmadpour
Oliver
O
Dolnak
Douglas
D
D000328:Adult; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use*; D014150:Antipsychotic Agents / Q000627:therapeutic use; D000068579:Celecoxib; D004311:Double-Blind Method; D004357:Drug Synergism; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009483:Neuropsychological Tests; D010919:Placebos; D011569:Psychiatric Status Rating Scales; D011720:Pyrazoles / Q000627:therapeutic use*; D012559:Schizophrenia / Q000188:drug therapy*; D013449:Sulfonamides / Q000627:therapeutic use*; D013997:Time Factors
D000894:Anti-Inflammatory Agents, Non-Steroidal; D014150:Antipsychotic Agents; D010919:Placebos; D011720:Pyrazoles; D013449:Sulfonamides; D000068579:Celecoxib